Replimune (REPL) Other financing activities (2018 - 2026)
Replimune (REPL) posted Other financing activities of $92000.0 for Q1 2026, down 88.37% sequentially from $791000.0 in Q4 2025, and up 187.5% YoY from $32000.0 in Q1 2025.
Replimune (REPL) Other financing activities (2018 - 2026) Analysis & Trends
Replimune has reported Other financing activities for 9 years, with the latest figure at $92000.0 in Q1 2026.
- Quarterly Other financing activities rose 187.5% year-over-year to $92000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $883000.0 (up 230.71% YoY) and the FY2026 annual result came in at $883000.0, up 230.71% from the prior year.
- Other financing activities retreated to $92000.0 in Q1 2026 per REPL's latest filing, from $791000.0 in the prior quarter.
- Over five years, Other financing activities peaked at $89.6 million in Q1 2023 and troughed at -$48.3 million in Q4 2024.
- A 5-year average of $6.4 million and a median of $645500.0 in 2022 frame the typical range for Other financing activities.
- The widest YoY moves for Other financing activities: up 3911.58% in 2024, down 2845.45% in 2024.
- Over 5 years, Other financing activities stood at $500000.0 in 2022, then jumped by 251.6% to $1.8 million in 2023, then tumbled by 2845.45% to -$48.3 million in 2024, then surged by 101.64% to $791000.0 in 2025, then tumbled by 88.37% to $92000.0 in 2026.
- According to Business Quant data, Other financing activities over the past three periods registered $92000.0, $791000.0, and $32000.0 for Q1 2026, Q4 2025, and Q1 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Replimune | 1.24 Bn | 1.24 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 92,000.00 |
| Mar 31, 2026 | 92,000.00 |
| Dec 31, 2025 | 791,000.00 |
| Dec 31, 2025 | 791,000.00 |
| Mar 31, 2025 | 32,000.00 |
| Mar 31, 2025 | 32,000.00 |
| Dec 31, 2024 | -48.27 Mn |
| Dec 31, 2024 | -48.27 Mn |
| Jun 30, 2024 | 48.50 Mn |
| Jun 30, 2024 | 48.50 Mn |
| Mar 31, 2024 | 1,000.00 |
| Mar 31, 2024 | 1,000.00 |
| Dec 31, 2023 | 1.76 Mn |
| Dec 31, 2023 | 1.76 Mn |
| Sep 30, 2023 | -1.21 Mn |
| Sep 30, 2023 | -1.21 Mn |
| Jun 30, 2023 | 1.21 Mn |
| Jun 30, 2023 | 1.21 Mn |
| Mar 31, 2023 | 89.61 Mn |
| Mar 31, 2023 | 89.61 Mn |